Posts in category Healthcare


Oppenheimer Casts 3Q Predictions: Teva Pharmaceutical Industries Ltd (ADR) (TEVA), Synergy Pharmaceuticals Inc (SGYP)

Derek Archila thinking twice before ready to bet on Teva’s turnaround, but Synergy could bring some upside.

Read more

Jason Kolbert Boosts Price Target for MannKind Corporation (MNKD) to $7; Here’s Why

Mannkind caught a price target boost from Maxim in the wake of a positive label revision for Afrezza.

Read more

BTIG Remains Buyer of Vericel Corp (VCEL) on Core Business Value

BTIG feels confident in Vericel core business as ixmyelocel-T’s future became uncertain.

Read more

ACADIA Pharmaceuticals Inc. (ACAD) Hits New 52-Week High Following Breakthrough Therapy Designation; J.P. Morgan Weighs In

ACAD receives BTD in dementia-related psychosis; Initiates DRP phase 3 trial; Phase 2 SERENE trial discontinued.

Read more

Why You Should Hold Your Horses with Teva Pharmaceutical Industries Ltd (ADR) (TEVA) and Valeant Pharmaceuticals Intl Inc (VRX)

TEVA needs a long-term solution after MYL’s generic Copaxone approval; VRX works on its debt problem.

Read more

Celsion Corporation (CLSN) Wins Over Maxim’s Bullish Blessing, Catabasis Pharmaceuticals Inc (CATB) Has Cowen Encouraged After Promising Pivotal DMD Phase II Trial Results

Celsion strikes iron while its hot to raise $15.6 million; Catabasis slows rate of DMD decline in OLE trial.

Read more

Sorrento Therapeutics Inc (SRNE) Has Competitive Advantage to Claim Meaningful Share in Lidocaine Patch Market, Cheers H.C. Wainwright

Analyst spotlights a compelling commercial future ahead for Sorrento’s ZTlido in post-herpetic neuralgia.

Read more

Biotech Universe: Mizuho Expects Mylan N.V. (MYL) To Rally, Endocyte, Inc. (ECYT) Brings Wedbush Over To The Bulls

Analysts weigh in with confidence on two biotech stocks blasting through the roof this week.

Read more

Wall Street’s Take on Two Biotech Rockets: Mylan N.V. (MYL) and CytomX Therapeutics Inc (CTMX)

Cantor cautiously welcomes MYL’s FDA success as EPS upside; Cowen applauds CTMX’s Probody technology.

Read more

Valeant Pharmaceuticals Intl Inc (VRX) Keeps Fighting to Turnaround Debt Overhang, RedHill Biopharma Ltd – ADR (RDHL) Scares Investors to Save $14 Million; Analysts Dive In

Valeant’s comeback progresses with new notes offering; RedHill ups the risk ante in favor of time/money.

Read more